Deliverables
At least 500 mg of reactive ncAA AhA will be produced by biotechnological means
Bioproduction of unmodified spidroinsAt least 500 mg of unmodified spidroins will be biologically produced
Production of activated affinity ligandsAt least 250 mg of each activated affinity ligand will be attained The affinity ligands selective for factor VIII Mabs VLPs and protein A will be produced and modified with DBCO for further modification of labeled spidroin
Data Management PlanA detailed Data Management Plan will be created at the beginning of the project to ensure that all data is findable accessible interoperable and reusable FAIR The plan will be harmonized with a knowledge protection plan IPR plan
Dissemination and Exploitation Plan at the end of the first Reporting Period RP1 M12
Publications
Author(s):
Charlotte Leonhardt
Published in:
2021
Publisher:
Universitat Bayreuth
Author(s):
Amelie Linder
Published in:
2022
Publisher:
Universitat Bayreuth
Author(s):
José Pedro Fradique Lourenço Dias Dinis
Published in:
2022
Publisher:
Universidade NOVA de Lisboa
Author(s):
Costa, Carlos Filipe Santos; Barbosa, Arménio J. M.; Dias, Ana Margarida Gonçalves Carvalho; Roque, Ana Cecília A.
Published in:
Biotechnology Advances, Issue 59, 2022, Page(s) 107986, ISSN 0734-9750
Publisher:
Elsevier BV
DOI:
10.1016/j.biotechadv.2022.107986
Searching for OpenAIRE data...
There was an error trying to search data from OpenAIRE
No results available